Health authorities have initiated a targeted vaccination programme aimed at one million teenagers and young adults following heightened concerns about meningitis B cases. The campaign will prioritize individuals considered at the highest immediate risk, with a focus on protecting vulnerable age groups from meningococcal disease.
Meningitis is an infection affecting the protective membranes surrounding the brain and spinal cord. While it can impact any age group, it occurs most frequently in babies, young children, teenagers, and young adults. The condition can prove severe without prompt treatment. Infections may be caused by bacteria or viruses, which can be identified through testing. Bacterial meningitis, though less common than viral meningitis, tends to be more serious and may lead to blood poisoning, sepsis, or brain damage. Meningitis B accounts for the majority of severe meningococcal disease cases in the UK, with 378 cases of invasive meningococcal disease recorded in 2024-2025.
Symptoms of meningitis develop rapidly and may include high fever, severe headache, neck stiffness, vomiting, diarrhea, joint and muscle pain, sensitivity to light, cold extremities, seizures, confusion, and extreme fatigue. A characteristic non-blanching rash that does not disappear when pressed with glass may also appear. Early recognition and medical intervention are critical, as treatment can be lifesaving.
Two primary vaccines provide protection against major meningitis causes. The MenACWY vaccine protects against four bacterial groups and is offered to 14-year-olds, with free access available until age 25. The MenB vaccine protects against meningococcal group B and is administered to infants at eight weeks, 12 weeks, and one year. The new targeted programme this summer will offer Year 13 pupils and individuals under 25 entering university or residential further education two free vaccine doses. Meningitis B spreads through close contact via respiratory droplets or saliva exchange in coughs, sneezes, kissing, or shared items. Transmission risk increases in shared accommodation settings typical of university environments. Invasive disease typically peaks from October to November annually.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI